Gabapentin Capsule
Product Images NDC 71205-766

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-766). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-766-90 (Gabapentin 300mg 30s)

Label for Gabapentin 300 mg capsules by Proficient Rx LP, containing 90 capsules. Each capsule contains 300 mg of gabapentin, USP, and is described as white to off-white powder in size 1 hard gelatin capsules with opaque yellow cap and body, imprinted with SG on cap and 180 on body in black ink. Manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY. Storage instructions and patient medication guide recommendation included.*

FDA Label Image

Figure 1 (Image 01)

A line graph comparing mean pain scores over eight weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, starting at baseline through week 8, while the y-axis represents mean pain scores. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over 7 weeks comparing placebo with Gabapentin at dosages of 1800 mg/day and 2400 mg/day. The X-axis represents time in weeks with distinct 3-week titration and 4-week fixed dose periods, while the Y-axis shows the mean pain score.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' shows data from two studies. Study 1 compares placebo (12%) and GBP 3600 (29%), while Study 2 compares placebo (14%), GBP 1800 (32%), and GBP 2400 (34%). Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula depicting the calculation for creatinine clearance (CLCr), involving age, weight, sex adjustment factor, and serum creatinine values.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin showing a cyclohexane ring attached to a backbone with amine and carboxylic acid functional groups. This structure represents the active ingredient gabapentin in the prescription drug capsule form.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing differences (%) versus daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The x-axis represents daily doses ranging from 600 to 1800 mg, and the y-axis shows percent difference from 2 to 22%. Study a is depicted with black squares, study b with gray squares, and study c with white squares, each showing increasing differences at higher doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.